On Wednesday, Allogene Therapeutics Inc (ALLO) stock saw a decline, ending the day at $2.72 which represents a decrease of $-0.12 or -4.23% from the prior close of $2.84. The stock opened at $2.86 and ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Allogene Therapeutics (ALLO – Research Report) today and set a price target ...

Piper Sandler analyst Biren Amin lowered the firm’s price target on Allogene Therapeutics (ALLO) to $9 from $11 and keeps an Overweight rating on the shares. The firm notes Allogene announced the ...

ALLO Fiber has kicked off the return of ALLO for Education, a program where they support local schools throughout their fiberhoods. The program's success in the past has been a benefit to their ...

A formal ceremony took place today following the start of construction on Joplin’s new fiber-optic network. A groundbreaking ...

Allogene Therapeutics Inc (ALLO) reports a strong cash position and promising clinical progress, despite facing competitive ...

A groundbreaking in Joplin celebrates what officials hope will be a step towards a more connected city. City leaders joined ...

Q3 2024 Earnings Call Transcript November 7, 2024 Allogene Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Construction has officially begun on ALLO’s state-of-the-art, 100% fiber-optic network in Joplin as of November 4.

Allogene Therapeutics has reported phase 1 data on its solid tumor CAR-T, linking the off-the-shelf cell therapy candidate to ...

BACKGROUND: Allogeneic stem cell transplantation (allo-SCT) is an efficacious treatment for hematologic malignancies but can ...

Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Thank you for standing by. My name is Bella, and I will be your ...